RONALD W. HART

Corporate Board Profile

Tech Score: 0/100

GUIDED THERAPEUTICS INC

Filing Date	Source Excerpt
2015-07-31	Two of our directors, Ronald W. Hart and John E. Imhoff are participating in the Series C Transaction. At the second closing, they will exchange their shares of Series B preferred stock, in lieu of making a cash payment, on a dollar-for-dollar basis, on the same terms as each other investor in the Series C Transaction. Dr. Hart currently holds 25 shares of Series B preferred stock, convertible into 239,120 shares of common stock. He will receive 33 shares of Series C preferred stock, initially convertible into 347,368 shares of common stock (assuming the current conversion price has not changed), and a warrant to purchase an additional 521,053 shares of common stock at an exercise price of $0.095 per share.

Filing Date

Source Excerpt

2015-07-31

Two of our directors, Ronald W. Hart and John E. Imhoff are participating in the Series C Transaction. At the second closing, they will exchange their shares of Series B preferred stock, in lieu of making a cash payment, on a dollar-for-dollar basis, on the same terms as each other investor in the Series C Transaction. Dr. Hart currently holds 25 shares of Series B preferred stock, convertible into 239,120 shares of common stock. He will receive 33 shares of Series C preferred stock, initially convertible into 347,368 shares of common stock (assuming the current conversion price has not changed), and a warrant to purchase an additional 521,053 shares of common stock at an exercise price of $0.095 per share.

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22